Effectiveness and Safety of Early Insulin Glargine U100 and Glargine U300 Administration in the Management of Diabetic Ketoacidosis in Adults With Type 1 Diabetes Mellitus: A Randomized Clinical Trial
Authors' conclusion
Early combination iGlar U100 or iGlar U300 with intravenous insulin infusion was associated with faster resolution of DKA and reduced total insulin requirements without increasing the risk of hypoglycemia or hypokalemia. Both iGlar U100 and U300 displayed similar safety and efficacy.
Study context
- Population
- Adults with T1D diagnosed with diabetic ketoacidosis (DKA)randomized into 3 groups
- Participants
- 90 adults
- Comparison
- Early SC iGlar U100 or iGlar U300 plus IV insulin vs IV insulin alone
Methodological details3-arm
- 3-arm
Primary result
As reported in the abstract
Time to DKA resolution
iGlar U100 vs Control: P < 0.001 · iGlar U300 vs Control: P < 0.001 · Between iGlar U100 and iGlar U300: P = 0.693
Further findings
| Outcome | P value |
|---|---|
| Total insulin doseBetween iGlar U100 and iGlar U300 · no significant difference | P = 0.908 |
Total insulin dose
- Both iGlar U100 and iGlar U300 required significantly lower total insulin dose vs control
Safety
- Hypoglycemia incidence similar across the 3 groups
- P = 0.871
- Hypokalemia incidence similar across the 3 groups
- P = 0.657
- Rebound hyperglycemia incidence similar across the 3 groups
- P = 0.718
- Rebound DKA incidence similar across the 3 groups
- P = 1
Original publication
Effectiveness and Safety of Early Insulin Glargine U100 and Glargine U300 Administration in the Management of Diabetic Ketoacidosis in Adults With Type 1 Diabetes Mellitus: A Randomized Clinical Trial. Endocr Pract. Published 19 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →